Stockreport

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Arcellx, Inc.  (ACLX) 
PDF -- Presented positive preliminary data at ASH 2024 from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel in patients with RRMM which demonstrate [Read more]